Explore an asset’s potential to clear all technical and regulatory hurdles and receive FDA approval.
![Assess current pipeline with real-time AI-driven PTRS for faster, more confident decisions.](https://www.intelligencia.ai/wp-content/uploads/2024/02/Icon-access-current-pipeline@2x.png)
Assess current pipeline with real-time AI-driven PTRS for faster, more confident decisions.
![Gain transparency and context with AI Explainability with PTRS drivers to understand the impact they have on the assessment.](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-ai-explainability@2x.png)
Gain transparency and context with AI Explainability with PTRS drivers to understand the impact they have on the assessment.
![See phase transition for industry-led, interventional, FDA-track trials.](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-phase-transition@2x.png)
See phase transition and PTRS for industry-led, interventional FDA-track trials, including that of competitors.
![Explore clinical programs which include one or more clinical trials showing the progress of a specific drug (or combination of drugs) through clinical development phases.](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-explorer@2x.png)
Explore how a specifc drug or combinations of drugs advance through clinical development phases
![Access to comprehensive, granular, disease-specific benchmarks.](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-benchmark@2x.png)
Access comprehensive, granular, disease-specific benchmarks.
![](https://www.intelligencia.ai/wp-content/uploads/2024/03/funnel-icon-1.png)
View clinical outcomes by phase, arm and cohort and access primary and secondary endpoints to understand clinical design by specific indication.
Together, Let’s Drive Your Strategic Portfolio Management Forward
Increase R&D ROI
Save between $8-25M* per year, by reducing the number of failed Phase 2 and Phase 3 trials.
- Augment internal discussions consistently and calibrate PTRS assessments across assets
- Save resources associated with PTRS elicitation and calibration
- Challenge internal thinking and reduce subjectivity and biases
- Improve resource allocation by stopping less-promising projects early
*Based on failed trials only in oncology and I&I
**Based on blockbuster drug
Accelerate Time to Market
Save between $2-5M per month of delayed launch of a single asset** by accelerating investment decision-making.
- Reduce number of risk elicitation and alignment meetings
- Increase data and explainability transparency
- Make faster decisions and accelerate execution speed
*Based on failed trials only in oncology and I&I
**Based on blockbuster drug
Make Smarter Deals
Save between $3-5M per in-licensing deal in upfront payments for every 5% points of miscalculated PTRS.
- Apply the same level of rigor for internal assets
- Reduce information asymmetry during valuation
- Reduce number of missed-out opportunities due to risk over-estimation
*Based on failed trials only in oncology and I&I
**Based on blockbuster drug
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-challenge@2x.png)
Challenge
Expensive and time-consuming expert elicition and KOL process.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-solution@2x.png)
Solution
Leverage Portfolio Optimizer to complement and enhance internal process with consistent and comprehensive data.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-benefits@2x.png)
Benefits
Save valuable resources while minimizing manual effort and human bias.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-challenge@2x.png)
Challenge
Limited data and high risk on early stage licensing. High-costs and competition on later stage assets.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-solution@2x.png)
Solution
Use Portfolio Optimizer to compare PTRS of various candidates, assess them against objective benchmarks, and compare the competitive landscape to support your valuation efforts.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-benefits@2x.png)
Benefits
Identify promising assets earlier and more confidently by incorporating data-driven probability of success assessment to support your business case and negotiations.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-challenge@2x.png)
Challenge
Lack of consistent and comprehensive benchmarking data make for difficult decisions on which drug candidates to move forward.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-solution@2x.png)
Solution
Use Portfolio Optimizer to inform decisions on therapeutic area expansion, indication and phase benchmarking to rank drug development opportunities.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-benefits@2x.png)
Benefits
Leverage objective assessments to generate a list of prioritized assets and foster internal alignment and understand where your asset fits in the competitive landscape.
Our Industry-Leading Accuracy Is Validated With Four Distinct Methods
Our Industry-Leading Accuracy Is Validated With Four Distinct Methods
![Retrospective Accuracy](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-retrospective-accuracy@2x.png)
Retrospective Accuracy
Area under the curve (AUC) is a metric which indicates whether the model assigns higher probability to the approved programs higher than the failed ones. The higher the AUC the better.
![Sensitivity/ Specificity](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-sensitivity-specificity@2x.png)
Sensitivity/ Specificity
The True Positive (sensitivity) and True Negative (specificity) rates highlight the ability of the model to correctly identify approved and rejected programs, accordingly. The higher the rates the better.
![Brier Score Loss](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-brier-score-loss@2x.png)
Brier Score Loss
Brier Score Loss (BSL) is a metric that quantifies the accuracy of probability predictions. BSL penalizes high probabilities of failed programs and low probabilities of approved programs. The lower the BSL the better.
![Prospective Accuracy](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-prospective-accuracy@2x.png)
Prospective Accuracy
The Calibration Curve measures prospectively how closely the predicted probabilities match the actual and observed outcomes, helping to understand the reliability of the model.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-molecule-indication-level@2x.png)
Access to depth and breadth of data based on unique program entity that goes beyond the molecule-indication level.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-phase-by-phase@2x.png)
See both phase-by-phase and path-by-path analyses for better facilitating data-driven decision-making that captures a more comprehensive view of the clinical development path.
![](https://www.intelligencia.ai/wp-content/uploads/2024/02/icon-flexibility-and-cutomization@2x.png)
Customize your search with dynamic filtering to slice-and-dice data and surface relevant, real-time data.